Fresenius Q3/26 adjusted core net income rises 15% to €403 million

Bitget2026/11/04 05:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fresenius Q3/26 adjusted core EPS rose 15% year over year to EUR 0.72.
Revenue before special items climbed 6% to EUR 5.8 billion; EBIT margin before special items widened to 11%.
An exclusive development agreement with WuXi Biologics provides access to up to 37 potential first-to-market biosimilar candidates.
The group raised its FY26 EBIT margin indication before special items to above 11.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2427898_en) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fresenius Q3/26 adjusted core net income rises 15% to €403 million

You may also like

Crypto prices